Skip to content

Trial Summary

In this study we plan to evaluate the maximum tolerated dose (MTD) of the drug Abraxane, which can be safely given to patients concurrently with radiotherapy in locally advanced pancreatic cancer (LAPC).

Acronym:

ART in Lap

ACTRN/NCT /ethics:

ACTRN12613001013752
Ethics: 132.12

Scientific title:

Phase I open label trial of Abraxane (nab-paclitaxel) administered concurrently with radiotherapy in patients with locally advanced inoperable pancreatic adenocarcinoma.

Sponsor / Cooperative group:

Sourthern Adelaide Local Health Network

Trial & Patient Characteristics

Cancer TypePancreas
Trial TypeTreatment
PhasePhase I
Age Range18 years and older
SexBoth
Tumour Stream Locally Recurrent or Locally Advanced
Cancer StageInsert
Anticipated Start Date2013-09-09
Anticipated End Date-

Participating Hospitals

HospitalFlinders Medical Centre
Clinical Trial CoordinatorAlex Scott-Hoy
Emailalex.scott-hoy@sa.gov.au
Phone08 8204 4830
Principal InvestigatorProfessor Chris Karapetis
Recruitment StatusRecruitment on Hold
HospitalThe Queen Elizabeth Hospital
Clinical Trial CoordinatorPamela Cooper
Emailpamela.cooper@sa.gov.au
Phone08 8222 6140
Principal Investigator-
Recruitment StatusRecruitment on Hold
HospitalRoyal Adelaide Hospital
Clinical Trial CoordinatorAnne Milton
Emailanne.milton@sa.gov.au
Phone08 70742342
Principal InvestigatorSinghal
Recruitment StatusRecruitment on Hold